Pink Sheet senior writers Derrick Gingery and Sarah Karlin-Smith, senior editors Brenda Sandburg and Sue Sutter, and Executive Editor Nielsen Hobbs discuss the questions that emerged from two US Food and Drug Administration advisory committee meetings on RSV vaccines, Eli Lilly and Company’s plan to lower insulin prices, a new definition that could be added to the Orphan Drug Act and the departure of Billy Dunn as director of the FDA’s Office of Neuroscience.
Pink Sheet Podcast: RSV Vaccine Questions, Lilly Lowers Insulin Cost, Orphan Drug Act Changes
Pink Sheet reporters and editors discuss US FDA advisory committee members’ concerns about two proposed RSV vaccines, Lilly’s plan to lower the cost of its insulin products, proposed changes to the Orphan Drug Act, and the departure of the influential leader of the FDA’s neuroscience office.
